Adrenal gland responses to lipopolysaccharide after stress and ethanol administration in male rats.

All forms of stress, including restraint stress (RS) and lipopolysaccharide (LPS) administration, activate the hypothalamic-pituitary-adrenal (HPA) axis. LPS binds to a recognition protein (CD14) and toll-like receptor 2/4 in different cells and tissues, including the adrenal gland, to induce the production of cytokines and cause upregulation of cyclooxygenase and nitric oxide synthase (NOS) enzymes. Acute ethanol exposure activates the HPA axis, but in some conditions prolonged administration can dampen this activation as well as decrease the inflammatory responses to LPS. Therefore, this study was designed to evaluate the adrenal response to a challenge dose of LPS (50 µg/kg) injected i.p., after submitting male rats to RS, twice a day (2 h each time) for 5 days and/or ethanol administration (3 g/kg) by gavage also for 5 days, twice daily. At the end of the experiment, plasma corticosterone concentrations and adrenal gland content of prostaglandin E (PGE) and NOS activity were measured as stress mediators. The results showed that repetitive ethanol administration attenuated the adrenal stress response to LPS challenge alone and after RS, by preventing the increase in plasma corticosterone concentrations and by decreasing the PGE content and NOS activity in the adrenal gland. Therefore, we conclude that moderate alcohol consumption could attenuate the effects of psychophysical stress and impair an inflammatory response.

Inducible nitric oxide synthase gene expression in the brain during systemic inflammation.

Inducible nitric oxide synthase (iNOS) is a transcriptionally regulated enzyme that synthesizes nitric oxide from L-arginine that has a key role in the pathophysiology of systemic inflammation and sepsis. Transgenic animals with a null mutation for the iNOS gene are resistant to hypotension and death caused by Escherichia coli lipopolysaccharide (LPS). The regulation of peripheral iNOS has been well studied in sepsis, but little is known about iNOS regulation in the brain during systemic inflammation or sepsis. We know that at baseline there is no detectable iNOS gene expression in the brain, but a detailed neuroanatomical study reveals that early in the course of systemic inflammation there is a profound induction of iNOS messenger RNA in vascular, glial and neuronal structures of the rat brain, accompanied by the production of nitric oxide (NO) metabolites in brain parenchyma and cerebrospinal fluid (CSF). We propose that the spillover of nitrite into the CSF has the potential to be a diagnostic marker for systemic inflammation and sepsis. Pharmacological interventions aimed at regulating iNOS function in the brain might represent a new treatment strategy in sepsis. Brain iNOS may be relevant to the pathophysiology, diagnosis and treatment of systemic inflammation and sepsis.

Expression and function of endocannabinoid receptors in the human adrenal cortex.

Endogenous cannabinoids are important signaling molecules in neuroendocrine control of homeostatic and reproductive functions including stress response and energy metabolism. The hypothalamic paraventricular and supraoptic nuclei have been shown to release endocannabinoids, which act as retrograde messengers to modulate the synaptic release of glutamate during stress response. This study endeavors to elucidate possible interaction of the endocannabinoid system with the regulation of adrenocortical function at the adrenal level. Human adrenocortical NCI-H295R cells and normal human adrenal glands were used to study the possible effects of anandamide and cannabinoid receptor 1 (CB1) antagonist SR141716A on aldosterone and cortisol secretion. Our data indicate the expression of CB1 in human adrenal cortex and adrenocortical NCI-H295R cells; CB2 was not expressed. Furthermore, anandamide inhibited basal release and stimulated release of adrenocortical steroids (corticosterone and aldosterone); this effect was reversed by CB1 antagonist (SR141716A). Therefore, the endocannabinoid system at the level of the adrenal, can directly influence adrenocortical steroidogenesis.

The role of toll-like receptors in the immune-adrenal crosstalk.

Sepsis and septic shock remain major health concerns worldwide, and rapid activation of adrenal steroid release is a key event in the organism's first line of defense during this form of severe illness. Toll-like receptors (TLRs) are critical in the early immune response upon bacterial infection, and recent data from our lab demonstrate a novel link between the innate immune system and the adrenal stress response mediated by TLRs. Glucocorticoids and TLRs regulate each other in a bidirectional way. Bacterial toxins acting through TLRs directly activate adrenocortical steroid release. TLR-2 and TLR-4 are expressed in human and mice adrenals and TLR-2 deficiency is associated with an impaired glucocorticoid response. Furthermore, TLR-2 deficiency in mice is associated with marked cellular alterations in adrenocortical tissue. TLR-2-deficient mice have an impaired adrenal corticosterone release following inflammatory stress induced by bacterial cell wall compounds. This defect appears to be associated with a decrease in systemic and intraadrenal cytokine expression. In conclusion, TLRs play a crucial role in the immune-adrenal crosstalk. This close functional relationship needs to be considered in the treatment of inflammatory diseases requiring an intact adrenal stress response.

The nitric oxide theory of aging revisited.

Bacterial and viral products, such as bacterial lipopolysaccharide (LPS), cause inducible (i) NO synthase (NOS) synthesis, which in turn produces massive amounts of nitric oxide (NO). NO, by inactivating enzymes and leading to cell death, is toxic not only to invading viruses and bacteria, but also to host cells. Injection of LPS induces interleukin (IL)-1beta, IL-1alpha, and iNOS synthesis in the anterior pituitary and pineal glands, meninges, and choroid plexus, regions outside the blood-brain barrier. Thereafter, this induction occurs in the hypothalamic regions (such as the temperature-regulating centers), paraventricular nucleus (releasing and inhibiting hormone neurons), and the arcuate nucleus (a region containing these neurons and axons bound for the median eminence). Aging of the anterior pituitary and pineal with resultant decreased secretion of pituitary hormones and the pineal hormone melatonin, respectively, may be caused by NO. The induction of iNOS in the temperature-regulating centers by infections may cause the decreased febrile response in the aged by loss of thermosensitive neurons. NO may play a role in the progression of Alzheimer's disease and parkinsonism. LPS similarly activates cytokine and iNOS production in the cardiovascular system leading to coronary heart disease. Fat is a major source of NO stimulated by leptin. As fat stores increase, leptin and NO release increases in parallel in a circadian rhythm with maxima at night. NO could be responsible for increased coronary heart disease as obesity supervenes. Antioxidants, such as melatonin, vitamin C, and vitamin E, probably play important roles in reducing or eliminating the oxidant damage produced by NO.

Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge.

Neuropeptide Y (NPY) is a peptide found in a variety of hypothalamic loci which is frequently colocalized with catecholamines. It is also secreted into hypophyseal portal vessels. The injection of NPY into the third ventricle (3V) lowered plasma GH levels in conscious, freely moving male rats. To determine the physiological significance of the hypothalamic inhibitory action of the peptide, highly specific antiserum directed against NPY was injected into the 3V of conscious rats. 3V injection of the antiserum evoked a significant elevation of plasma GH within 2 h on comparison to values in normal rabbit serum-injected, ovariectomized rats. The difference increased and reached a maximum at 6 h after injection. On the other hand, there was no effect of the antiserum in ovariectomized, estrogen, progesterone-blocked rats. Intraventricular injection of the anti-NPY serum also caused a significant elevation of plasma GH within 2 h in normal male rats and the increases above values in normal rat serum-injected control animals became even more significant at 3 and 4 h. To determine the mechanism by which NPY lowers GH after its intraventricular injection, its effect on the release of somatostatin (SRIF) from median eminence fragments incubated in vitro was examined. NPY stimulated SRIF release with a highly significant effect at a concentration of 10(-9) M. Borderline stimulation was observed at doses as low as 10(-11) M. The curve was bell-shaped with a declining release at 10(-8) M and 10(-7) M. The releasing action of NPY was blocked by either the alpha 1-receptor blocker, prazosin (10(-6) M), or the beta-receptor blocker, propranolol (10(-6) M), but was not affected by the alpha 2-receptor blocker, yohimbine (10(-6) M). We conclude that NPY has a physiologically significant inhibitory action within the hypothalamus to suppress GH release in ovariectomized female and intact male rats by stimulation of SRIF release by alpha 1 and beta-adrenergic receptor-mediated mechanisms.

Effects of porcine follicular fluid on gonadotropin concentrations in rhesus monkeys.

The administration of steroid-free charcoal-treated porcine follicular fluid to long term castrated female rhesus monkeys lowered basal serum concentrations of FSH and had almost no effect on serum LH. Treatment with porcine follicular fluid before the administration of exogenous LRH inhibited the release of FSH, but also affected the release of LH. This inhibition was especially striking on the suppression of the peak of release of both FSH or LH at 20 min. These findings suggest that an inhibin-like material present in follicular fluid could play an important role in the secretion of FSH and LH in rhesus monkeys.

Effects of ethanol on intraovarian nitric oxide production in the prepubertal rat.

Nitric oxide (NO) has been shown to contribute to ovarian development and function. In non-ovarian tissues NO can be altered by ethanol (ETOH), a drug considered to be a gonadal toxin in men as well as male and female rats. The present study was undertaken to determine if some of the detrimental effects of chronic ETOH exposure on prepubertal ovarian function could be due to ETOH-induced alterations in the intraovarian NO system. Rats were implanted with intragastric cannulae on day 24 and began receiving control or ETOH diets on day 29. All rats were killed on day 34, determined to be in the late juvenile stage of development, and their ovaries and blood were collected. We analyzed the expression of the two constitutive forms of nitric oxide synthase (NOS), i.e. neuronal (n) NOS and endothelial (e) NOS, as well as the inducible (i) form of NOS protein in the ovaries of control and ETOH-treated rats by Western immunoblotting. Results demonstrate that eNOS protein increased markedly (P<0.02; 140 kDa) in ETOH-treated rats compared with controls. ETOH treatment did not alter the protein expression of nNOS (155 kDa) and only slightly increased that of iNOS (130 kDa). We also assessed NOS activity as determined by nitrite accumulation and by the conversion of L-[14C]arginine to L-[14C]citrulline. In this regard, the ETOH-treated animals showed an increase in ovarian nitrite generation (P<0.05), as well as an increase in ovarian citrulline formation (P<0.0001), when compared with control animals. Along with the above described ETOH-induced increases in ovarian eNOS and NO activity, the serum levels of estradiol were concomitantly suppressed (P<0.001) in the ETOH-treated rats. These results demonstrate for the first time the ETOH-induced changes in the prepubertal ovarian NO/NOS system, and suggest that these alterations contribute to the detrimental actions of the drug on prepubertal ovarian development and function.

Inhibition by naloxone of the rise in hypothalamic dopamine and serum prolactin induced by ethanol.

We investigated the effect of naloxone on the concentration of dopamine in the hypothalamus and on the concentration of prolactin in serum and anterior pituitary of male rats acutely treated with ethanol. Acute ethanol administration increased serum prolactin levels and hypothalamic dopamine concentration. Pituitary prolactin was not modified by this treatment. Naloxone administered 15 min before the animals were sacrificed decreased serum prolactin levels and hypothalamic dopamine concentration in ethanol-treated rats. These results suggest that ethanol increases prolactin secretion because it decreases the release of dopamine by the hypothalamus. Naloxone decreases prolactin release probably because it antagonizes the inhibitory action of opioids on dopaminergic neurons.

Role of nitric oxide and alcohol on gonadotropin release in vitro and in vivo.

Alcohol suppresses reproduction in humans, monkeys, and small rodents by suppressing release of luteinizing hormone (LH). The major action is on the hypothalamus to decrease release of LH-releasing hormone (LHRH). The release of LHRH is controlled by nitric oxide (NO) as determined by in vivo and in vitro experiments. The hypothesized pathway is via norepinephrine (NE)-induced release of NO from NOergic neurons, which activates LHRH release. We have evaluated details of this process in male rats by incubating medial basal hypothalamic (MBH) explants in vitro and examining the release of NO and metabolites generated by NO that control LHRH release. NE increased release of NO as measured by determining the content of the enzyme at the end of the experiment (30 min) by adding [14C]arginine to the homogenate and measuring its conversion to [14C]citrulline since this is formed in equimolar quantities with NO by NO synthase (NOS). Because this increase in content, presumably caused by activation of the enzyme by NE, was blocked by the alpha 1 receptor blocker prazosin, it appears that alpha 1 receptors activate NOS by increasing intracellular free calcium in the NOergic neurons, which combines with calmodulin to activate NOS. The release of LHRH induced by nitroprusside (NP), a donor of NO, is accompanied by an increase in cyclic guanosine monophosphate (cGMP) in the medium supporting the activation of guanylate cyclase by NO. This activation is important in releasing LHRH since addition of 8-monobutyryl cGMP also released the peptide. Ethanol had no effect on the content of NOS or on the increase in content induced by NE, indicating that it did not act on NOS. Earlier experiments indicated that prostaglandin E2 (PGE2) was important in releasing LHRH. PGE2 is produced by activation of cyclooxygenase by NO since this occurred following addition of the NO donor, NP. Not only does NP increase PGE2 release, but it also increases the conversion of [14C]arachidonic acid to its metabolites, particularly PGE2, by activating cyclooxygenase. NP also activated lipoxygenase as indicated by increased release of leukotrienes, which also stimulate LHRH release. Ethanol acts at this step, because it completely blocked the release of PGE2, leukotrienes, and LHRH induced by NP. Therefore, the results support the theory that NE acts to stimulate NO release from NOergic neurons. This NO diffuses to the LHRH terminals, where it activates guanylate cyclase, leading to an increase in cGMP. At the same time, it also activates cyclooxygenase and lipoxygenase. The increase in cGMP increases intracellular free calcium, required for activation of phospholipase A2. Phospholipase A2 converts membrane phospholipids into arachidonic acid, the substrate for conversion by the activated cyclooxygenase and lipoxygenase to PGE2 and leukotrienes that activate the release of LHRH. Because alcohol inhibits conversion of labeled arachidonic acid to PGE2 and leukotrienes, it must act either directly to inhibit cyclooxygenase and lipoxygenase or by some other mechanism which, in turn, inhibits the enzyme. We initially believed that the action of alcohol was exerted directly on the LHRH terminals; however, our recent experiments indicate that alcohol suppresses LHRH release, at least in part, by stimulating beta-endorphinergic neurons that inhibit the release of NE, which drives the NOergic release of LHRH.

Control of salivary secretion by nitric oxide and its role in neuroimmunomodulation.

In many in vivo systems exposure to endotoxins (LPS) leads to the co-induction of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which is important to the regulation of the function of different systems during infection. In submandibular glands (SMG) neural (n)NOS is localized in neural terminals and in striated, granular convoluted and excretory ducts, endothelial (e)NOS in vascular endothelium and ducts, and iNOS in macrophages and in tubules and ducts. In normal adult male rats, injection of an inhibitor of NOS decreased the stimulated salivary secretion and a donor of NO potentiated it, indicating that NO exerts a stimulatory role. A single high dose of LPS (5 mg/kg, i.p.) induced an increase in NOS activity measured by the 14C-citrulline method, increased PGE content almost 100% as measured by RIA, and blocked stimulated salivary secretion. The administration of a specific iNOS inhibitor, aminoguanidine (AG), with LPS not only decreased NOS activity but significantly decreased PGE content, indicating that NO triggered the activation of COX-2. LPS increased conversion of labeled arachidonate to prostaglandins (PGs) showing that COX was induced. Since a PGE1 analogue blocked stimulated salivation, the LPS-induced inhibition of salivation is probably due to release of PGs. Therefore, the use of inhibitors of iNOS and COX-2 could be very useful to increase salivation during infection since saliva has antimicrobial actions.

The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection.

During infection, bacterial and viral products, such as bacterial lipopolysaccharide (LPS), cause the release of cytokines from immune cells. These cytokines can reach the brain by several routes. Furthermore, cytokines, such as interleukin-1 (IL-1), are induced in neurons within the brain by systemic injection of LPS. These cytokines determine the pattern of hypothalamic-pituitary secretion that characterizes infection. IL-2, by stimulation of cholinergic neurons, activates neural nitric oxide synthase (nNOS). The nitric oxide (NO) released diffuses into corticotropin-releasing hormone (CRH)-secreting neurons and releases CRH. IL-2 also acts in the pituitary to stimulate adrenocorticotropic hormone (ACTH) secretion. On the other hand, IL-1 alpha blocks the NO-induced release of luteinizing hormone-releasing hormone (LHRH) from LHRH neurons, thereby blocking pulsatile LH but not follicle-stimulating hormone (FSH) release and also inhibiting sex behavior that is induced by LHRH. IL-1 alpha and granulocyte macrophage colony-stimulating factor (GMCSF) block the response of the LHRH terminals to NO. The mechanism of action of GMCSF to inhibit LHRH release is as follows. It acts on its receptors on gamma-aminobutyric acid (GABA)ergic neurons to stimulate GABA release. GABA acts on GABAa receptors on the LHRH neuronal terminal to block NOergic stimulation of LHRH release. IL-1 alpha inhibits growth hormone (GH) release by inhibiting GH-releasing hormone (GHRH) release, which is mediated by NO, and stimulating somatostatin release, also mediated by NO. IL-1 alpha-induced stimulation of PRL release is also mediated by intrahypothlamic action of NO, which inhibits release of the PRL-inhibiting hormone dopamine. The actions of NO are brought about by its combined activation of guanylate cyclase-liberating cyclic guanosine monophosphate (cGMP) and activation of cyclooxygenase (COX) and lipoxygenase (LOX) with liberation of prostaglandin E2 and leukotrienes, respectively. Thus, NO plays a key role in inducing the changes in release of hypothalamic peptides induced in infection by cytokines. Cytokines, such as IL-1 beta, also act in the anterior pituitary gland, at least in part via induction of inducible NOS. The NO produced inhibits release of ACTH. The adipocyte hormone leptin, a member of the cytokine family, has largely opposite actions to those of the proinflammatory cytokines, stimulating the release of FSHRF and LHRH from the hypothalamus and FSH and LH from the pituitary directly by NO.

Role of nitric oxide in the neuroendocrine responses to cytokines.

During infection, bacterial and viral products, such as bacterial lipopolysaccharide (LPS), cause the release of cytokines from immune cells. These cytokines can reach the brain by several routes. Furthermore, cytokines, such as interleukin-1 (IL-1), are induced in neurons within the brain by systemic injection of LPS. These cytokines determine the pattern of hypothalamic-pituitary secretion which characterizes infection. IL-2, by stimulation of cholinergic neurons, activates neural nitric oxide synthase (nNOS). The nitric oxide (NO) released diffuses into corticotropin-releasing hormone (CRH)-secreting neurons and releases CRH. IL-2 also acts in the pituitary to stimulate adrenocorticotropic hormone (ACTH) secretion. On the other hand, IL-1 alpha blocks the NO-induced release of luteinizing hormone-releasing hormone (LHRH) from LHRH neurons, thereby blocking pulsatile LH but not follicle-stimulating hormone (FSH) release and also inhibiting sex behavior that is induced by LHRH. IL-1 alpha and granulocyte macrophage colony-stimulating factor (GMCSF) block the response of the LHRH terminals to NO. The mechanism of action of GMCSF to inhibit LHRH release is as follows. It acts on its receptors on gamma-aminobutyric acid (GABA)ergic neurons to stimulate GABA release. GABA acts on GABAa receptors on the LHRH neuronal terminal to block NOergic stimulation of LHRH release. This concept is supported by blockade of GMCSF-induced suppression of LHRH release from medial basal hypothalamic explants by the GABAa receptor blocker, bicuculline. IL-1 alpha inhibits growth hormone (GH) release by inhibiting GH-releasing hormone (GHRH) release, which is mediated by NO, and stimulating somatostatin release, also mediated by NO. IL-1 alpha-induced stimulation of prolactin release is also mediated by intrahypothalamic action of NO, which inhibits release of the prolactin-inhibiting hormone dopamine. The actions of NO are brought about by its combined activation of guanylate cyclase-liberating cyclic guanosine monophosphate (cGMP) and activation of cyclooxygenase and lipoxygenase with liberation of prostaglandin E2 and leukotrienes, respectively. Thus, NO plays a key role in inducing the changes in release of hypothalamic peptides induced in infection by cytokines. Cytokines, such as IL-1 beta, also act in the anterior pituitary gland, at least in part via induction of inducible NOS. The NO produced inhibits release of anterior pituitary hormones.

In vivo and in vitro effects of neuropeptide K and neuropeptide gamma on the release of growth hormone.

There is anatomical and experimental evidence suggesting that tachykinins have a role in the regulation of secretion of anterior pituitary hormones. In this investigation, the effects of neuropeptide K and neuropeptide gamma on the secretion of GH were studied in vivo and in vitro. Injections of neuropeptide K into the third ventricle of freely moving, ovariectomized rats resulted in a significant increase of plasma GH, but neuropeptide gamma induced no significant changes in these levels, although it did induce a significant increase in GH pulse height. In vitro, neither neuropeptide K nor neuropeptide gamma had any apparent effect on GH release from hemipituitaries incubated for 2 h. These results suggest that neuropeptide K may have a modulatory function in the regulation of GH secretion from the anterior pituitary, through an action exerted at the hypothalamic level, and the effects of neuropeptide gamma seem to be more marginal.

Nitric oxide synthase-independent release of nitric oxide induced by KCl in the perfused mesenteric bed of the rat.

The aim of the present study was to test whether the contractile responses elicited by KCl in the rat mesenteric bed are coupled to the release of nitric oxide (NO). Contractions induced by 70 mM KCl were coincident with the release of NO to the perfusate. The in vitro exposure to the nitric oxide synthase (NOS) inhibitor L-N(omega)-nitro-L-arginine methyl ester, L-NAME (1-100 microM) potentiated the vascular responses to 70 mM KCl and, unexpectedly, increased the KCl-stimulated release of NO. Moreover, even after the chronic treatment with L-NAME (70 mg/kg/day during 4 weeks), the KCl-induced release of NO was not reduced, whereas the potentiation of contractile responses was indeed achieved. The possibility that NOS had not been completely inhibited under our experimental conditions can be precluded because NOS activity was significantly inhibited after both L-NAME treatments. After the in vitro treatment with 1 to 100 microM L-NAME, the inhibition of NOS was concentration-dependent (from 50% to 90%). With regard to the basal release of NO, the inhibition caused by L-NAME was not concentration-dependent and reached a maximum of 40%, suggesting that basal NO outflow is only partially dependent on NOS activity. An eventual enhancement of NOS activity caused by KCl was disregarded because the activity of this enzyme measured in homogenates from mesenteric beds perfused with 70 mM KCl was significantly reduced. On the other hand, endothelium removal, employed as a negative control, almost abolished NOS activity, whereas the incubation with the Ca(2+) ionophore A23187, employed as a positive control, induced an increase in NOS activity. It is concluded that in the mesenteric arterial bed of the rat, the contractile responses elicited by depolarization through KCl are coincident with a NOS-independent release of NO. This observation, which differs from the results obtained with noradrenaline, do not support the use of KCl as an alternative contractile agent whenever the participation of NO is under study.

The effect of acute ethanol administration on GABA receptor binding in cerebellum and hypothalamus.

The effect of the intraperitoneal administration of ethanol on [3H]GABA binding and glutamic acid decarboxylase (GAD) in cerebellum and hypothalamus was investigated. Acute ethanol administration produced an increase in the binding capacity of the high affinity GABA binding sites and a decrease in the binding capacity of low affinity sites. A decrease in the binding capacity of the high affinity GABA binding sites and an increase in the binding capacity of the low affinity sites were observed in the hypothalamus. No apparent changes were detected in the binding affinities for the two types of GABA receptor sites in both brain areas following ethanol treatment. Ethanol enhanced GAD activity in the cerebellum and reduced GAD activity in the hypothalamus. Changes in GABA binding may be involved in some of the neuropharmacological effects of ethanol.

Physiologic and pharmacologic studies on the motility of isolated guinea pig ovaries.

The spontaneous motility of ovaries isolated from guinea pigs in early and late proestrus and estrus was explored. The influences of oxytocin, prostaglandin F2alpha (PGF2alpha), and adrenergic agonists and antagonists were also studied. Spontaneous ovarian isometric developed tension (IDT) and rate of contractions (RC) were greater in late proestrus than in early proestrus or estrus. Furthermore, in late proestrus, oxytocin and PGF2alpha induced ovarian motilities of comparable magnitude and significantly greater than those elicited in other stages of the cycle. Norepinephrine and phenylephrine either failed to alter or inhibited IDT and RC of ovaries in estrus, but stimulated motility in the presence of propranolol. The depressive influence of norephinephrine upon the IDT of ovaries in early proestrus was not seen in late proestrus, when the neurotransmitter was clearly stimulating. The hormonal status of guinea pigs seems to influence spontaneous ovarian motility as well as pharmacologic reactivity to several agents, including those presumably acting upon alpha- and beta-adrenergic receptors.

Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.

The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects. Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out. Control patients received infusions of 0.9% NaCl solution. During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.

Nitric oxide mediates the stimulation of luteinizing-hormone releasing hormone release induced by glutamic acid in vitro.

Previous experiments from our laboratory have indicated that LHRH release is controlled in vivo and in vitro by NO. Since glutamic acid, the major excitatory transmitter in the brain, has been shown to release LHRH, we wished to determine whether or not this LHRH release was mediated by NO. Consequently, arcuate-median eminence explants from normal male rats were incubated in vitro in Krebs-Ringer bicarbonate glucose (KRBG) media in a Dubnoff metabolic shaker for a preincubation period of 30 min. Fresh media were added containing the substances to be tested and incubation was continued for 30 min. Sodium nitroprusside (NP, 500 microM), which releases NO spontaneously, stimulated the release of LHRH, which indicates that NO can release LHRH. Glutamic acid (10 mM) also produced a robust release of LHRH, and this release was blocked by the inhibitor of NO synthase, NG-monomethyl-L-arginine (NMMA). Furthermore, the release of LHRH induced by glutamic acid was prevented by the addition of hemoglobin (20 micrograms/ml), a scavenger of NO, which would remove the NO released by the action of glutamic acid. The results indicate that glutamic acid stimulated LHRH release is induced by NO.

Glutamic acid induces luteinizing hormone releasing hormone release via alpha receptors.

Glutamic acid (GA) and norepinephrine (NE) stimulate luteinizing hormone-releasing hormone (LHRH) release via release of nitric oxide (NO) from NOergic neurons in the arcuate-median eminence region. To determine if GA releases LHRH via direct stimulation of NOergic neurons, or via stimulation of noradrenergic terminals, arcuate median eminence explants from male rats were incubated with various compounds, and the LHRH release into the medium was measured. GA-induced release of LHRH was completely blocked by phentolamine (1 microM), an alpha receptor blocker, which, by itself, had no effect on the release. Nitroprusside (NP), which spontaneously releases NO, more than doubled LHRH release. To determine if alpha receptors on the LHRH neuron are required for the action of NP, the tissue was incubated with phentolamine, plus NP. Phentolamine had no effect on the LHRH-releasing action of NP. The results are interpreted to mean that GA activates the release of NE from the noradrenergic terminals. This acts on alpha receptors on the NOergic neuron to produce the release of NO. This NO diffuses to the LHRH terminals and induces release of LHRH.